Table 1.

The weak association between the prevalence of HPV16 and host immune status relative to that for other oncogenic HPV types

HPV typesRatio of the OR (95% CI)*
HPV16 (reference)1.00
HPV182.05 (0.97-4.34)
HPV312.62 (1.02-6.71)
HPV332.97 (1.09-8.13)
HPV352.66 (1.08-6.55)
HPV395.24 (1.39-19.7)
HPV453.49 (1.39-8.80)
HPV512.56 (1.06-6.19)
HPV523.03 (1.35-6.80)
HPV562.55 (1.14-5.72)
HPV582.70 (1.09-6.68)
HPV594.42 (1.72-11.4)
HPV665.85 (2.55-13.5)
  • *The ratio of ORs was estimated using a GEE logistic regression model [model (1.4)] examining the associations of host immune status with the prevalent detection of HPV by type, with HPV16 as the reference type. For convenience, the table shows only the contrast between HIV-positive women with CD4+ count <200 cells/mm3 and HIV viral load >100,000 copies/mL versus HIV-negative women. The adjustment variables included age at visit (<30, 30-34, 35-39, 40-44, ≥45 y), race (White, Black, Hispanic, and other), sexual partners in the past 6 mo [none, 1 (married), 1 (single), 2, and >2], and smoking status (none, former smoker, current smoker <10 packs per year, and current smoker ≥10 packs per year).